Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

Affiliations

¹ Department of Oncology and Hemato-Oncology, Università degli Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. salvatore.siena@unimi.it.
² Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
⁴ The Cancer Institute Hospital of JFCR, Tokyo, Japan.
⁵ National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
⁶ Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
⁷ Medical Oncology Department, Clinica Universidad de Navarra, Navarra, Spain.
⁸ Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
⁹ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
¹⁰ Kindai University Hospital, Osaka, Japan.
¹¹ Daiichi Sankyo, Basking Ridge, NJ, USA.
¹² Daiichi Sankyo, Co., Ltd, Tokyo, Japan.
¹³ West Cancer Center, Germantown, TN, USA.
¹⁴ National Cancer Center Hospital East, Kashiwa, Japan.

Published Erratum

Salvatore Siena et al. Nat Commun. 2025.

. 2025 Jan 15;16(1):704.

doi: 10.1038/s41467-025-56170-9.

¹ Department of Oncology and Hemato-Oncology, Università degli Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. salvatore.siena@unimi.it.
² Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
⁴ The Cancer Institute Hospital of JFCR, Tokyo, Japan.
⁵ National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
⁶ Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
⁷ Medical Oncology Department, Clinica Universidad de Navarra, Navarra, Spain.
⁸ Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
⁹ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
¹⁰ Kindai University Hospital, Osaka, Japan.
¹¹ Daiichi Sankyo, Basking Ridge, NJ, USA.
¹² Daiichi Sankyo, Co., Ltd, Tokyo, Japan.
¹³ West Cancer Center, Germantown, TN, USA.
¹⁴ National Cancer Center Hospital East, Kashiwa, Japan.

No abstract available

Erratum for

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, Yoshino T. Siena S, et al. Nat Commun. 2024 Nov 25;15(1):10213. doi: 10.1038/s41467-024-53223-3. Nat Commun. 2024. PMID: 39587050 Free PMC article. Clinical Trial.